companiesCompany
Xcovery
aka Xcovery Holdings, Inc.
Xcovery is the Florida company that developed ensartinib, an ALK inhibitor approved by the FDA in December 2024 for ALK-positive non-small-cell lung cancer, partnered with Betta Pharmaceuticals in China where it was approved first.
Overview
Xcovery Holdings, based in Palm Beach Gardens, Florida, developed ensartinib (Ensacove), a second-generation ALK inhibitor. Its Chinese partner Betta Pharmaceuticals won approval there in 2020, and the FDA approved ensartinib in December 2024 for ALK-positive locally advanced or metastatic non-small-cell lung cancer in patients not previously treated with an ALK inhibitor, on the eXalt3 trial against crizotinib. Company facts are from the official website and FDA approval records.
Headquarters
Palm Beach Gardens, FL, US
Scorecard
All companies#123of 779 companies, score 22
- approved products +6
- targets +2
- modalities +2
- regions +2
- registry trials +10
1 approved, 0 in phase 3, 0 earlier, 1 targets, 27 registry studies. Formula on the scorecards page.
Type
biotech
Stage
Growth stage
Website